Multimodal Management of Anti‐ GBM Disease Complicated by Secondary Complement‐Mediated Thrombotic Microangiopathy in a Patient Intolerant to Plasma Exchange: A Case Report
Therapeutic Apheresis and Dialysis · 2026-12 · 30 (6) · 839-846
DOI: 10.1002/1744-9987.70172 ↗Kurz gefasst
Fallbericht in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 08.06.2026. Verfasst von Xiangyu Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu…. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Plasma Exchange, Anti-Glomerular Basement Membrane Disease. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Chengdu Medical Research Project.
Abstract (Originalsprache)
Background
Anti‐glomerular basement membrane (anti‐GBM) disease complicated by thrombotic microangiopathy (TMA) is rare and clinically challenging. In the setting of severe infection and active autoimmune disease, complement activation may reflect a secondary process rather than primary atypical hemolytic uremic syndrome (aHUS). Therapeutic plasma exchange (TPE) is standard therapy for anti‐GBM disease, but alternative antibody removal strategies are required when TPE is not tolerated. Case Presentation We describe a 46‐year‐old female with anti‐GBM disease who developed TMA with preserved ADAMTS13 activity (72.04%) and 2.3% schistocytes on peripheral smear. Soluble C5b‐9 was elevated in the context of severe concurrent infection. TPE was discontinued due to intolerance (oxygen desaturation, fever, and dizziness). Seven sessions of protein A immunoadsorption (PAIA) were performed for selective antibody removal, and anti‐GBM antibody levels decreased from > 400 to 20.80 RU/mL during treatment. Eculizumab was administered on Days 7, 14, and 30, for persistent complement activation. Hematologic and biochemical parameters stabilized and gradually improved during combined therapy.
Conclusion
This case suggests that PAIA may represent a feasible alternative antibody removal strategy in anti‐GBM disease intolerant to plasma exchange. In selected cases of secondary complement‐mediated TMA with ongoing complement activation, short‐term complement inhibition may contribute to disease stabilization; however, a definitive causal relationship cannot be established in a single case.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Renal Department and Nephrology Institute, Sichuan Provincial People's Hospital, Chengdu, China.
ORCID-Profile: Xiangyu Yang, Shasha Chen, Wei Wang
Förderung
- Chengdu Medical Research Project
Zitieren
APA
Yang, X., Guo, P., Ma, L., Chen, S., & Wang, W. (2026). Multimodal Management of Anti‐ GBM Disease Complicated by Secondary Complement‐Mediated Thrombotic Microangiopathy in a Patient Intolerant to Plasma Exchange: A Case Report. Therapeutic Apheresis and Dialysis, 30(6), 839-846. https://doi.org/10.1002/1744-9987.70172
Vancouver
Yang X, Guo P, Ma L, Chen S, Wang W. Multimodal Management of Anti‐ GBM Disease Complicated by Secondary Complement‐Mediated Thrombotic Microangiopathy in a Patient Intolerant to Plasma Exchange: A Case Report. Therapeutic Apheresis and Dialysis. 2026;30(6):839-846. doi:10.1002/1744-9987.70172
BibTeX
@article{Yang2026,
author = {Yang, Xiangyu and Guo, Ping and Ma, Lisha and Chen, Shasha and Wang, Wei},
title = {Multimodal Management of Anti‐ GBM Disease Complicated by Secondary Complement‐Mediated Thrombotic Microangiopathy in a Patient Intolerant to Plasma Exchange: A Case Report},
journal = {Therapeutic Apheresis and Dialysis},
year = {2026},
volume = {30},
number = {6},
pages = {839--846},
doi = {10.1002/1744-9987.70172}
}
EUVIMED